#### Research Article

For reprint orders, please contact: reprints@futuremedicine.com

# Lung Cancer Management



# Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid

Rodney E Wegner\*,<sup>1</sup>, Stephen Abel<sup>1</sup>, Zachary D Horne<sup>1</sup>, Shaakir Hasan<sup>1</sup>, Athanasios Colonias<sup>1</sup> & Vivek Verma<sup>1</sup>

<sup>1</sup>Allegheny Health Network Cancer Institute, Division of Radiation Oncology, 320 E. North Ave, Pittsburgh, PA 15212, USA

Aim: To compare trends and outcomes in early stage bronchopulmonary carcinoid (BPC) tumors treated nonoperatively with conventionally fractionated radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT). Methods/materials: We queried the National Cancer Database for primary (typical) BPC staged cT1-2N0M0 and treated nonsurgically with lung-directed radiation and  $\geq 1$  month of follow-up. Odds ratios were used to predict likelihood of SBRT treatment and multivariable Cox regression determined predictors of survival. Results: Out of 154 patients, 84 (55%) were treated with SBRT and the remainder were treated with CFRT. Although SBRT use was 0% from 2004 to 2007, it varied from 50 to 70% per year thereafter. Propensity-matched Kaplan–Meier analysis revealed improved survival with lung SBRT (median: 66 vs 58 months; p = 0.034). Conclusion: SBRT for early stage, primary BPC has increased over time and was associated with higher survival than CFRT.

First draft submitted: 13 February 2019; Accepted for publication: 27 June 2019; Published online: 21 August 2019

Keywords: bronchopulmonary carcinoid • lung cancer • NSCLC • SBRT

#### **Background**

Low-grade neuroendocrine tumors of the lung, traditionally referred to as typical pulmonary carcinoids, are rare and usually follow an indolent clinical course [1–3]. For patients able to undergo surgery, resection remains the preferred management and standard of care, resulting in excellent local control (>95%) [4–6]. Often, these tumors occur in older patients not amenable to surgical resection due to medical comorbidities. In this situation, radiation is considered a reasonable alternative [7].

In more recent years, stereotactic body radiotherapy (SBRT) has emerged as an efficacious method to deliver ablative doses of radiation to lung tumors, typically in medically inoperable patients with non-small-cell lung cancer (NSCLC) [8,9]. In this setting, as compared with conventionally fractionated radiation therapy (CFRT), SBRT has shown to have improved outcomes and is preferred in appropriately selected patients, resulting in increased utilization over the past 10–15 years [10].

However, the experience with SBRT for pulmonary carcinoids is much more limited, being reported in only a few small series [11,12]. SBRT for these neoplasms may be particularly beneficial owing to the relatively radioresistant nature [13]. As such, we sought to use the National Cancer Database (NCDB) to examine trends and outcomes with the use of SBRT as compared with CFRT.

# **Methods**

The methods for analyzing the NCDB have been previously outlined [14–16]. This retrospective review comprised de-identified data from the NCDB, therefore, an IRB waiver was permitted. Overseen by the American Cancer Society and American College of Surgeons, the NCDB encompasses an estimated 70% of annual cancer cases in the USA. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator.



<sup>\*</sup>Author for correspondence: Tel.: +1 412 359 3400; Fax: +1 412 359 3171; Rodney.wegner@ahn.org




Figure 1. CONSORT diagram showing patient selection.

AJCC: American Joint Committee on Cancer; EBRT: External beam radiation therapy; SBRT: Stereotactic body radiotherapy; TNM: Tumor, nodes, metastasis.

Patients with documented clinical stage T1-2N0 typical pulmonary carcinoid who were treated nonoperatively with radiation to the lung were included in this study (atypical carcinoids were not included in this study due to the small number treated with SBRT or even CFRT). Figure 1 is a CONSORT diagram outlining the cohort selection criteria. We excluded patients not receiving radiation, treated with surgery, or having unknown/inadequate (i.e., < 1 month) follow-up to account for immortal time bias.

Race was categorized as Caucasian, African American or other. The Charlson/Deyo comorbidity index quantified the degree of comorbidities [17]. Socioeconomic data in the patients' residence census tract were divided into quartiles

based upon the percentage of persons with less than a high school education and median household income. Facility type was grouped according to the Commission on Cancer accreditation category. Locations were described based on data provided by the US Department of Agriculture Economic Research Service. Insurance status is documented in the NCDB as it appears on the admission page.

Data were analyzed using Medcalc Version 18 (Ostend, Belgium). Summary statistics are presented for discrete variables. Chi-squared tests compared sociodemographic treatment and tumor characteristics between the treatment groups. Overall survival is recorded in the NCDB in months from time of diagnosis to death or censored at last contact. Kaplan–Meier curves were used to calculate cumulative probability of survival [18]. Of note, outcomes like local failure, regional failure, distant failure as well as salvage therapy are not included in the NCDB. Log-rank statistics were used to test for a statistically significant difference in the cumulative proportions across groups. A multivariable survival analysis was conducted using a Cox proportional hazards model [11]. Factors significant on univariable analysis were entered using a stepwise elimination process. Adjusted hazard ratios and 95% confidence intervals are reported, using an alpha level of 0.05 to indicate statistical significance.

To account for indication biases associated with lack of randomization, propensity score-matching was applied to the multivariable survival analysis [19]. Multivariable logistic regression was used to calculate a propensity score indicative of conditional probability of receiving SBRT. The propensity model included observable variables associated with treatment selection on multivariable logistic regression. Patients were then matched based on propensity score and analyzed using Kaplan–Meier curves. The assumption of balance was further validated by stratifying the data into propensity score-based quintiles, and confirming that the difference in propensity score mean per quintile was less than 0.10.

#### Results

We identified 154 patients in the NCDB between 2004 and 2014 meeting the above eligibility criteria, of whom 84 (55%) were treated with SBRT. Table 1 outlines the baseline characteristics of the entire cohort. The median age was 74 years (interquartile range: 65–81), most patients (76%) were stage T1 and very few received systemic therapy (6%). Patients with T2 stage and receipt of chemotherapy were more likely to be treated with CFRT (Table 2). For patients treated with radiation, the rate of SBRT use was 0% from 2004 to 2007, thereafter, it varied from 50 to 70% per year. The median CFRT dose was 54 Gy (interquartile range: 50–60) in 24 fractions (interquartile range: 5–33) and the median SBRT dose was 50 Gy (interquartile range: 50–55 Gy) in four fractions (interquartile range: 4–5).

Median follow-up was 30 months (1–107 months) for the entire cohort. Multivariable analysis identified age < 74 years, SBRT technique, female sex and more recent year of diagnosis as predictive of improved survival (Table 3). Unadjusted Kaplan–Meier analysis demonstrated improved overall survival in patients receiving SBRT compared with patients receiving CFRT (median: 65 vs 58 months, p = 0.0184), as shown in Supplementary Figure 1. Propensity score was generated and incorporated education level and income level following multivariable logistic regression. Fifty-seven pairs were generated based on an exact propensity score match. Propensity-matched Kaplan–Meier analysis revealed improved survival with lung SBRT, median overall survival of 66 months compared with 58 months, p = 0.0344 (Figure 2). We also ran the propensity-matched Kaplan–Meier analysis including only T1 patients with survival benefit still seen with SBRT (median overall survival of 66 months compared with 58 months, p = 0.0171).

## Discussion

Pulmonary carcinoid tumors are relatively rare and are second to gastrointestinal sites in terms of location [12]. Surgical resection remains the preferred treatment, yielding local control rates >95% and allowing for sampling of nodal tissue at the time of intervention [20]. As evidenced by the population presented here (median age 74 years), these patients are often older and either cannot tolerate surgical intervention or refuse it. In those instances, radiation offers a reasonable alternative definitive treatment, extrapolating from many years of use of CFRT in NSCLC [21]. Over the past 10–15 years, lung SBRT has emerged as a highly effective and safe alternative to surgery, typically in nonoperable NSCLC patients [8–10,22]. Naturally, the use of SBRT for NSCLC and other lung tumors has sharply expanded over the past 10+ years [9].

The use of SBRT in pulmonary carcinoid, however, has been reported sparingly. A small case series from Yale reviewed outcomes in four patients with pulmonary carcinoid, all treated with SBRT in a safe and effective manner, lending some support to SBRT as an alternative in patients that do not get treated surgically [13]. Of note, in this

Table 1. Patient demographics and clinical characteristics at baseline (n = 154). Characteristics (manuface)		1 1 / 450
Sec         Hander         49 (80)           - Amalo         49 (80)           - Femalo         111 (72)           Rece         Herender           - White         130 (80)           - African-American         14 (90)           - Chother         1 (10)           - Chother         27 (20)           - 1         30 (20)           - 2         1 (20)           - 2         1 (20)           - 1         30 (20)           - 2         2 (20)           - 2         2 (20)           - 4         2 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 4         30 (20)           - 5         30 (20)           - 6		
-Asia         4) 28           -Fernale         11 (72)           Fernale         130 (80)           -Arkitan-Amerian         14 (9)           -Other         1 (1)           Comorbidity sore:		Number (%)
Fennale         111 (7)           Race           White         139 (8)           African, American         14 (9)           Cother         1 (1)           Comerbidity score         7 (2)           - 0         97 (8)           1         2 (2)           - 2         2 (2)           Invariance         1 (2)           - Private payer         30 (19)           - Ownerment         1 (2)           - Government         2 (2)           - Uncarded         2 (2)           - Uncarded         30 (39)           - Uncarded         2 (2)           - 2-28         2 (14)           2 0 248 3         30 (39)           - 14-139         30 (39)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         30 (29)           - 14-149         3		
Rober         Very late of the propose of the pro		
-White         139 000           -African American         140 (0           -African American         140 (0           Chere         140 (0           Compositivity sore         97 (60)           -2         20 (0           -1         37 (24)           -2         20 (0           Instrumence         100           - Frivate page         20 (0           - Government         20 (20)           - Owneronde         20 (0           Education (Nt)         100           - Propositive page         20 (0           - 14-19         20 (20)           - 29-28.9         20 (20)           - 4-19         30 (20)           - 4-19.9         60 (30)           - 4-19.9         60 (30)           - 4-19.9         60 (30)           - 4-19.9         20 (30)           - 4-19.9         60 (30)           - 4-19.9         20 (30)           - 4-19.9         20 (30)           - 4-19.9         20 (30)           - 4-20.0         20 (30)           - 4-20.0         20 (30)           - 4-20.0         20 (30)           - 8-20.0         20 (30)		111 (72)
- African-American         14 (%)           - Other         101           - Comerbidity sore:         - (%)           - 0         97 (%)           - 1         2 (%)           - 2         20 (3)           Insurance:         - (%)           - Note Insured         0 (%)           - Government         2 (2)           - Government         2 (2)           - Government         2 (2)           - 20-28-9         2 (3)           - 20-28-9         2 (3)           - 20-28-9         3 (2)           - 14-19-9         3 (2)           - 14-19-9         3 (2)           - 14-19-9         5 (3)           - 14-19-9         5 (3)           - 14-19-9         5 (3)           - Comprehens'cearch program         2 (1)           - Comprehens'cearch program         2 (1)           - Academic/research program         4 (3)           - Academic/research program         4 (3)           - Publa         4 (3)           - Publa         4 (3)           - Owner program         4 (3)           - Publa         4 (3)           - Publa         4 (3)           - Publ		
Gomerbidity score         1           0         97 (63)           1         37 (24)           2-2         20 (13)           Insurance         Western Hander           Perivate paper         30 (19)           6-Government         12 (29)           4-Government         22 (20)           2-Bustation (N):         Western Hander Hander           2-32-38         30 (39)           1-4-19.9         60 (39)           2-4-19.1         30 (20)           1-4-19.1         60 (39)           1-4-19.1         (40)           1-5-14         (40)           1-5-15         (40)           1-4-19.1         (40)           1-4-19.1         (40)           1-4-19.1         (40)           1-6-14         (40)           1-6-15         (40)           1-6-16         (40)           1-6-17         (40)           1-6-18         (40)           1-6-19         (40)           1-6-19         (40)           1-7-19         (40)           1-8-10         (40)           1-8-10         (40)           1-8-10         (40)		
Commerbidity sores         9 (63)           -1         37 (24)           -2         20 (13)           Insurance         West (15)           - Priotal payer         30 (19)           - Gowermant         122 (29)           - Unecorded         22 (14)           - 239         22 (14)           - 30-28 (9)         30 (23)           - 44-19.9         30 (23)           - 44-19.9         30 (23)           - 4-14.9         30 (23)           - Comment facility type:         30 (23)           - 14         30 (23)           - Comment facility type:         30 (23)           - Comment facility type:         41 (19)           - Comment facility type:         41 (19)           - Comment facility type:         41 (19)           - Mademi/research program         9 (8)           - Mademi/research program         12 (80)           - What         4 (30)           - What         4 (30)           - What         4 (30)           - What         4 (30)           - So,000 to 5,599         4 (30)           - A (30)         4 (30)           - Pad         4 (3)           - Pad		
-0         97 (63)           -1         37 (24)           -2         20 (13)           Insurance:         West Control           - Not insued         00(9)           - Government         122 (79)           - Government         122 (79)           - Unrecorded         22 (14)           - 30-28 (30)         36 (23)           - 14-19.9         60 (39)           - 4-14.9         60 (39)           - 4-14.9         10 (30)           - 6. Own munity cancer program         2 (1)           - Compenhensive community cancer program         2 (3)           - Compenhensive community cancer program         2 (3)           - Wetto         12 (80)           - Fademicry cancer program         2 (8)           - Wetto         12 (80)           - Further         2 (8)           - Further         2 (8)           - Further         3 (8)           - Further         3 (8)           - Further         4 (8)           - Further         3 (8)           - Further         4 (8)           - Support (10)         4 (8)           - Further         4 (8)           - Support (10)         4		1 (1)
-1         37 (24)           -2         00 (3)           Insurance         Westernament           - Not Insured         00 (9)           - Government         122 (79)           - Unrecorded         20 (2)           - Guerande         122 (10)           - Guardin (%):         21 (10)           - 20-28.9         30 (25)           - 14-19.9         60 (39)           (- 14 (- 19))         30 (22)           Treatment facility type:         Westernament facility type:           - Commentily cancer program         60 (45)           - Commentily cancer program         20 (45)           - Comprehensive community cancer program         20 (45)           - Commentily focation:         Westernament facility frongth           - Wind         25 (7)           - Rural         40 (3)           - Rural         40 (3)           - Subject         40 (3)		
	- 0	
Institutione		37 (24)
- Priota payer         3019           - Government         122 79           - Unrecorded         2 2           Education (%):         - Very Carlow           - 29         2 (14)           - 20-28.9         30 (25)           - 14-19.9         60 (39)           - 4-14         10 (30)           - Comprehensive community cancer program         2 (1)           - Comprehensive community cancer program         2 (5)           - Comprehensive community cancer program         82 (54)           - Rural         12 (180)           - Comprehensive community cancer program         82 (54)           - Rural         12 (80)           - Comprehensive community cancer program         82 (54)           - Rural         43 (20)           - Rural         4 (3)           - Suppose to program         4 (20)           - Suppose to program         4 (20)           - Suppose to program         4 (20)           - Suppose to progr	-≥2	20 (13)
- Private payer   20 (19) - Government   12 (19) - Covernment   12 (19) - Covernment   12 (19) - Covernment   12 (19) - Covernment   13 (19) - Community cancer program   20 (20) - Covernment facility location:  Treatment facility location:  Twitter   12 (20) - Covernment   20 (20) - Covernment   20 (20) - Covernment facility location:  Twitter   20 (20) - Covernment   20 (20) - Covernment	Insurance:	
- Government         122 (79)           - Unrecorded         2 (2)           Education (%):         22 (14)           - 20-28.9         39 (25)           - 14-19.9         60 (39)           - 4 (2)         32 (22)           Trestment facility type:         - (1)           - Community cancer program         69 (45)           - Academic/research program         69 (45)           - Academic/research program         121 (89)           - Wetro         12 (89)           - Uthan         25 (17)           - Rural         4 (3)           - Round         30 (19)           - 30,000         30 (19)           - 30,000         35,000           - 35,000 to 35,000         37 (24)           - 35,000 to 45,099         40 (29)           - 34,600         37 (3)           Politicular (miles)         37 (3)           - 21         2 (3)           Age distribution (years):         3 (3)           - 274         3 (3)           - 3007-209         4 (3)           - 2004-2006         4 (3)           - 2007-2019         4 (4)           - 2007-2029         14 (9)           - 2010-2012	- Not insured	0 (0)
- Unrecorded         2(2)           Education (%):            -29         (4)           -20-28.9         39 (25)           -14-19.9         60 (39)           -< (4)	- Private payer	30 (19)
Education (%):  - 2-30	- Government	
- 29.289         39.25)           - 14-11-19.9         60.39.           - < 14	- Unrecorded	2 (2)
-2-2-8.9         39 (25)           -14-19.9         60 (39)           -<14	Education (%):	
- 14-19.9	- ≥29	22 (14)
1-414         33 (2)           Treatment facility type:         Community cancer program         2 (1)           Comprehensive community cancer program         80 (45)           - Comprehensive community cancer program         82 (34)           Treatment facility location:         ****           - Metro         121 (80)           - Urban         25 (17)           - Rural         4 (3)           - Round         30 (19)           - S0,000         30 (19)           - 30,000 to 35,000         30 (2)           - 35,000 to 45,999         44 (29)           - 46,000         30 (2)           Distance to treatment facility (miles):         ***           - 210         75 (39)           Ape distribution (years):         ***           - 274         81 (53)           - > 74         3 (37)           Year of diagnosis:         ***           - 2004-2006         4 (3)           - 2004-2001         4 (3)           - 2013-2014         4 (3)           - 2013-2014         4 (3)           - 2013-2014         4 (3)           - 2013-2014         3 (3)           - 10         4 (3)           - 2013-2014	- 20-28.9	39 (25)
Treatment facility type:         2 (1)           Comprehensive community cancer program         69 (4)           Academi/research program         82 (4)           Treatment facility location:         121 (80)           - Urban         4 (3)           - Bural         4 (3)           - Bural         4 (3)           - Rural         30 (19)           - 30,000         30 (19)           - 30,000         4 (29)           - 35,000 ta 55,901         4 (29)           - 35,000 ta 55,992         4 (29)           - 46,000         4 (29)           - 510         7 (8)           - 520         7 (8)           - 2-10         7 (8)           - 2-10         7 (8)           - 2-10         7 (8)           - 2-10         7 (8)           - 2-10         7 (8)           - 2-10         7 (8)           - 2-10         1 (8)           - 2-10         1 (8)           - 2-10         1 (8)           - 2-10         1 (8)           - 2-10         1 (8)           - 2-10         1 (8)           - 2-10         1 (8)           - 2-10         1 (8)     <	- 14-19.9	60 (39)
- Community cancer program         20 (4)           - Comprehensive community cancer program         69 (45)           - Academic/research program         25 (45)           - Teatment facility location:         21 (80)           - Urban         25 (17)           - Rural         40 (3)           - Income, US dollars:         30 (19)           - 30,000 (10 (35),000         30 (19)           - 30,000 (10 (35),000         37 (24)           - 36,000 (10 (35),000         44 (29)           - 30 (30 (10 (35),000)         37 (29)           - 5 (10 (35),000)         47 (29)           - 3 (10 (35),000)         40 (29)           - 3 (10 (35),000)         40 (29)           - 3 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)           - 5 (10 (35),000)         40 (29)	- < 14	33 (22)
- Comprehensive community cancer program         69 (45)           - Academic/research program         82 (54)           Treatment facility location:         11 (80)           - Whetro         25 (17)           - Urban         40 (3)           - Rural         40 (3)           - Roune US dollars:	Treatment facility type:	
- Academic/research program         82 5(4)           Treatment facility location:         25 (17)           - Urban         25 (17)           - Rural         4(3)           Income, US dollars:	– Community cancer program	2 (1)
Treatment facility location:         121 (80)           - Metro         25 (7)           - Bural         40           - Counce, US dollars:         - Very Counce, US dollars:           - < 30,000         30 (19)           - 30,000 to 35,000         37 (24)           - 35,000 to 45,999         44 (29)           - > 46,000         37 (8)           Distance to treatment facility (miles):         - Very Counce, US (20)           - < 510         75 (8)           - 270         75 (8)           Age distribution (years):         - Very Counce, US (20)           - < 274         81 (53)           - > 74         3 (7)           - 2004 - 2006         4 (3)           - 2007 - 2009         4 (9)           - 2010 - 2012         6 (40)           - 2013 - 2014         7 (48)           T stage:         - Very Counce, US (20)           - 2 (2013 - 2014)         10 (76)           - 2 (2014 - 2012)         3 (24)           - 2 (2014 - 2012)         3 (24)           - 2 (2014 - 2013)         3 (24)           - 2 (2014 - 2014)         3 (24)           - 2 (2014 - 2014)         3 (24)           - 2 (2014 - 2014)         3 (24)	- Comprehensive community cancer program	69 (45)
- Metro         121 (80)           - Urban         25 (77)           - Rural         403           Income, US dollars:         - Security           - 30,000 to 35,000         30 (9)           - 35,000 to 45,999         44 (29)           - > 46,000         37 (8)           Distance to treatment facility (miles):         7 (8)           - ≤ 10         75 (8)           - > 70         7 (8)           - 24         7 (8)           - 274         81 (53)           - > 7 (3)         7 (3)           - 2004 - 2004         8 (3)           - 2004 - 2005         4 (3)           - 2004 - 2006         4 (3)           - 2004 - 2009         4 (3)           - 2004 - 2009         4 (8)           - 2010 - 2012         6 (40)           - 2013 - 2014         7 (8)           - 3 (2)         7 (8)           - 2 (3)         7 (8)           - 2 (3)         7 (8)           - 2 (3)         7 (8)           - 2 (3)         7 (8)           - 2 (3)         7 (8)           - 2 (3)         7 (8)           - 3 (3)         7 (8)           - 3 (3) <td< td=""><td>– Academic/research program</td><td>82 (54)</td></td<>	– Academic/research program	82 (54)
- Urban         25 (17)           - Rural         4 (3)           Income, US dollars:            - 2 30,000         30 (19)           - 30,000 to 35,000         37 (24)           - 35,000 to 45,999         42 (29)           - > 46,000         3 (28)           Distance to treatment facility (miles):         79 (51)           -> 10         75 (49)           Age distribution (years):         81 (53)           -> 74         81 (53)           -> 74         3 (47)           Year of diagnosis:         4 (3)           - 2004-2006         4 (3)           - 2007-2009         14 (9)           - 2013-2014         7 (48)           - 2013-2014         7 (48)           - 2013-2014         17 (76)           - 2         3 (74)           Chemotherapy:         - (44,94)	Treatment facility location:	
- Rural         4 (3)           Income, U5 dollars:         30 (19)           - 30,000         37 (24)           - 35,000 to 45,999         44 (29)           - 34,600         79 (51)           - > 10         75 (49)           - > 10         75 (49)           - ≥ 10         75 (49)           - ≥ 74         81 (53)           - ≥ 74         73 (47)           - ≥ 74         73 (47)           - 2004-2006         4 (3)           - 2004-2006         4 (9)           - 2004-2012         4 (9)           - 2013-2014         14 (9)           T stage:         1 (17 (5)           - 1         1 (7) (4)           - 2         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24)           - 2 (20)         3 (24) <td< td=""><td>- Metro</td><td>121 (80)</td></td<>	- Metro	121 (80)
Income, US dollars:           - < 30,000	– Urban	25 (17)
-30,000       30 (19)         -30,000 to 35,000       37 (24)         -35,000 to 45,999       44 (29)         -> 46,000       32 (8)         Distance to treatment facility (miles):         - ≤10	- Rural	4 (3)
-30,000 to 35,000       37 (4)         -55,000 to 45,999       46 (29)         -> 46,000       38 (38)         Distance to treatment facility (miles):         - ≤10	Income, US dollars:	
-35,000 to 45,999       44 (29         -> 46,000       43 (28)         Distance to treatment facility (miles):         -≤10	- < 30,000	30 (19)
-> 46,000       43 (28)         Distance to treatment facility (miles):         -> 410	– 30,000 to 35,000	37 (24)
Distance to treatment facility (miles):         - ≤10	- 35,000 to 45,999	44 (29)
- ≤ 10 c + 20 c + 2	->46,000	43 (28)
->10 75 (49) Age distribution (years): -≤74 81 (53) ->74 73 (47) Year of diagnosis: -2004-2006 4(3) -2007-2009 14(9) -2010-2012 62 (40) -2013-2014 74 (48) T stage: -1 1 5tage: -1 20 37 (24) Chemotherapy: -No 144 (94)	Distance to treatment facility (miles):	
->10 75 (49) Age distribution (years): - ≤74 81 (53) ->74 73 (47) Year of diagnosis: - 2004-2006 4 (3) - 2007-2009 14 (9) - 2010-2012 62 (40) - 2013-2014 74 (48) T stage: - 1 - 1 - 2 - 2 - 3 - 7 (49) Chemotherapy: - No 144 (94)		79 (51)
-≤74       81 (53)         ->74       73 (47)         Year of diagnosis:       -         -2004-2006       4 (3)         -2007-2009       14 (9)         -2010-2012       62 (40)         -2013-2014       74 (48)         T stage:       117 (76)         -2       37 (24)         Chemotherapy:       144 (94)		75 (49)
->74       73 (47)         Year of diagnosis:       -         - 2004-2006       4 (3)         - 2007-2009       14 (9)         - 2013-2012       62 (40)         - 2013-2014       74 (48)         T stage:       -         - 1       117 (76)         - 2       37 (24)         Chemotherapy:       -         - No       144 (94)		
Year of diagnosis:         - 2004-2006       4 (3)         - 2007-2009       14 (9)         - 2010-2012       62 (40)         - 2013-2014       74 (48)         T stage:       117 (76)         - 2       37 (24)         Chemotherapy:       144 (94)		
- 2004-20064 (3)- 2007-200914 (9)- 2010-201262 (40)- 2013-201474 (48)T stage:117 (76)- 237 (24)Chemotherapy:144 (94)		73 (47)
- 2007-200914 (9)- 2010-201262 (40)- 2013-201474 (48)T stage:- 1- 1117 (76)- 237 (24)Chemotherapy:- No- No144 (94)		
- 2010-2012       62 (40)         - 2013-2014       74 (48)         T stage:         - 1       117 (76)         - 2       37 (24)         Chemotherapy:         - No       144 (94)		
- 2013–2014       74 (48)         T stage:         - 1       117 (76)         - 2       37 (24)         Chemotherapy:         - No       144 (94)		
T stage:         - 1       117 (76)         - 2       37 (24)         Chemotherapy:         - No       144 (94)		
- 1       117 (76)         - 2       37 (24)         Chemotherapy:         - No       144 (94)	- 2013-2014	74 (48)
- 2     37 (24)       Chemotherapy:     - No       144 (94)	T stage:	
Chemotherapy:         - No         144 (94)	<u>-1</u>	117 (76)
– No 144 (94)	- 2	37 (24)
	Chemotherapy:	
- Yes 10 (6)	- No	144 (94)
	– Yes	10 (6)

Table 2. Comparative use of	stereotactic body rac	diotherapy by baselir	ne characteristi	cs in patients red	ceiving lung
radiation.	CERT ( 70) (0()	CDDT ( 04) (0()	0.11	05% 61	
Characteristic	CFRT (n = 70) (%)	SBRT (n = 84) (%)	Odds ratio	95% CI	p-value
Sex:	22 (22)	22 (27)			
– Male	20 (29)	23 (27)	1	Reference	
– Female	50 (71)	61 (73)	1.06	0.52–2.15	0.87
Race:					
– White	65 (93)	74 (88)	1	Reference	
– African American	5 (7)	9 (11)	1.58	0.50–4.96	0.43
– Other	0 (0)	1 (1)	2.64	0.11–65.87	0.55
Comorbidity score:					
- 0	43 (61)	54 (64)	1	Reference	
- 1	19 (27)	18 (21)	0.75	0.35–1.61	0.47
- ≥2	8 (12)	12 (15)	1.19	0.45-3.18	0.72
Age (years):					
- ≤74	38 (54)	43 (51)	1	Reference	
- > 74	32 (46)	41 (49)	1.13	0.60-2.14	0.70
Insurance:					
– Private payer	18 (26)	12 (14)	1	Reference	
- Government	51 (74)	71 (86)	2.09	0.93–4.71	0.08
Education:					
- ≥29%	13 (19)	9 (11)	1	Reference	
- 20-28.9	15 (21)	24 (29)	2.31	0.80–6.72	0.12
-14-19.9	27 (39)	33 (39)	1.77	0.66-4.75	0.26
-<14	15 (21)	18 (21)	1.73	0.58–5.16	0.32
	13 (21)	10 (21)	1.73	0.36-3.10	0.32
Facility type:	1 (1)	1 (1)	1	Deference	
- Community cancer program	1 (1)	1 (1)	1	Reference	0.00
- Comprehensive cancer program	31 (45)	38 (45)	1.23	0.07–20.40	0.89
- Academic/research program	37 (54)	45 (54)	1.22	0.07–20.12	0.89
Facility location:					
- Metro	59 (86)	62 (77)	1	Reference	
– Urban	9 (13)	16 (20)	1.69	0.69–4.12	0.25
– Rural	1 (1)	3 (3)	2.85	0.29–28.22	0.37
Income (USD):					
-<30,000	11 (16)	19 (23)	1	Reference	
- 30,000-35,000	16 (23)	21 (25)	0.76	0.28–2.04	0.59
- 35,000–45,999	17 (24)	27 (32)	0.92	0.35–2.40	0.86
- > 46,000	26 (37)	17 (19)	0.38	0.14-0.99	0.05
T stage:					
<b>-1</b>	45 (64)	72 (86)	1	Reference	
- 2	25 (36)	12 (14)	0.30	0.13-0.66	0.0026
Distant to facility:					
– ≤10 miles	36 (51)	43 (51)	1	Reference	
- >10 miles	34 (49)	41 (49)	1.01	0.54–1.90	0.98
Received chemotherapy:					
– No	62 (89)	82 (98)	1	Reference	
– Yes	8 (11)	2 (2)	0.19	0.04–0.92	0.0393
Year of diagnosis:	. ,			-	
- 2004–2006	4 (6)	0 (0)	1	Reference	
- 2007-2009	7 (10)	7 (8)	9.00	0.41–198.22	0.16
- 2010-2012	27 (39)	35 (42)	11.62	0.60–225.09	0.10
<b>– 2013–2015</b>	32 (45)	42 (50)	11.77	0.61–226.50	0.10

patients' residence census tract.

Table 3. Multivariable Cox regression for predictors of survival in patients with pulmonary carcinoid treated with					
radiation therapy.					
Characteristic	HR (95% CI)	p-value			
Age (years):					
<b>- ≤74</b>	Reference				
- >74	2.06 (1.16–3.67)	0.0134			
Radiation technique:					
- CFRT	Reference				
- SBRT	0.48 (0.28–0.85)	0.0110			
Sex:					
– Male	Reference				
– Female	0.51 (0.27–0.94)	0.0305			
Year of treatment:					
- 2004–2006	Reference				
- 2007–2009	0.36 (0.14–0.95)	0.0396			
- 2010-2012	0.52 (0.16–1.66)	0.2723			
- 2013-2014	0.52 (0.27–1.04)	0.0628			




Figure 2. Overall survival comparison between patients with typical carcinoid treated with either conventionally fractionated radiation therapy or stereotactic body radiotherapy. Median survival was 66 months compared with 58 months, in favor of SBRT, p = 0.0344.

EBRT: External beam radiation therapy; SBRT: Stereotactic body radiotherapy.

analysis we did not directly compare surgical resection to SBRT, instead focusing on the difference in radiation techniques. We did show, after propensity matching that the patients treated with SBRT had better survival, suggesting a benefit compared with CFRT. One must keep in mind that patients with T2 tumors and those receiving chemotherapy were more likely to receive CFRT. Granted, the receipt of chemotherapy for stage T1-2N0 typical pulmonary carcinoid does not follow recognized guidelines, and likely implies some other undocumented clinicopathologic factors contributing to worse outcome. In addition, the tumor location was not reported and centrally located tumors may not be as amenable to SBRT and are more likely to cause symptoms or potential patient demise [23–25]. Another consideration is the ability of SBRT to deliver a higher biologically effective dose,

which one would expect to result in better outcomes given the relative radioresistance of carcinoids [13]. Taking all of the above into account, SBRT may be the preferred technique in nonoperative candidates with pulmonary carcinoid.

The limitations of the current study include its retrospective nature and inherent selection bias as a result. The NCDB also lacks critical data as it relates to operability such as performance status, extent of work up, pulmonary function testing and tumor location as mentioned above. The NCDB also does not record outcomes outside of survival, such as local failure, regional failure and any salvage therapy, which are all important and interrelated to survival in this patient population.

#### Conclusion

This analysis of the NCDB shows a steady increase in the use of SBRT for typical pulmonary carcinoids managed in a nonoperative fashion. There was a survival benefit seen with SBRT compared with CFRT, which persisted on propensity matching. In light of the sharply expanding use of SBRT over CFRT for other early stage lung tumors, SBRT may be considered as the preferred option for T1-2N0 pulmonary carcinoids.

### **Summary points**

- Historically, early stage bronchopulmonary carcinoid has been treated with surgery or conventionally fractionated radiotherapy (CFRT).
- Stereotactic body radiotherapy (SBRT) has emerged as the preferred treatment approach in inoperable cases of non-small-cell lung cancer; however, data in cases of primary typical lung carcinoid are limited.
- We performed a retrospective review of a large, contemporary database, analyzing 154 patients with early stage lung carcinoid treated with CFRT (n = 70) or SBRT (n = 84) from 2004 to 2014.
- SBRT use was 0% from 2004 to 2007, but increased to 50 to 70% per year thereafter and overall survival was longer (median: 66 months versus 58 months; p = 0.034) in those receiving SBRT compared with CFRT.
- SBRT may be considered as the preferred treatment option for nonoperative early stage patients.

#### Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/full/ 10.2217/lmt-2019-0003

#### **Author contributions**

RE Wegner performed project conception and design, statistical analysis and manuscript drafting. S Abel, ZD Horne and A Colonias did manuscript revisions. S Hasan performed statistical analysis and manuscript revisions. V Verma performed manuscript revision, project conception and design.

#### Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.


# Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

#### References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

- 1. Buschi AJ, Smith TH. Bronchial carcinoid. VA Med. Mon. 102(12), 1027–1031 (1976).
- Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 113(1), 5–21 (2008)
- Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92(8), 2204–2210 (2001).



- Carretta A, Ceresoli GL, Arrigoni G et al. Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44
  cases. Lung Cancer 29(3), 217–225 (2000).
- Ferguson MK, Landreneau RJ, Hazelrigg SR et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur. J. Cardiothorac. Surg. 18(2), 156–161 (2000).
- Filosso PL, Oliaro A, Ruffini E et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J. Thorac. Oncol. 8(10), 1282–1288 (2013).
- Mackley HB, Videtic GM. Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park) 20(12), 1537–1545, 1549 (2006).
- 8. Timmerman R, Paulus R, Galvin J *et al.* Stereotactic body radiation therapy for inoperable early stage lung cancer. *JAMA* 303(11), 1070–1076 (2010).
- 9. Hasan S, Colonias A, Mickus T, Vandeusen M, Wegner RE. Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: predictors from a 10-year single institution experience. *Thorac. Cancer* 9(6), 699–706 (2018).
- 10. Haque W, Verma V, Polamraju P, Farach A, Butler EB, Teh BS. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small-cell lung cancer. *Radiother. Oncol.* 129(2), 264–269 (2018).
- 11. Cox DR. Regression models and life- tables. J. R. Stat. Soc. 34(2), 187-220 (1972).
- 12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97(4), 934-959 (2003).
- Robust analysis of carcinoid management prior to the substantial increase in stereotactic body radiotherapy utilization.
- 13. Colaco RJ, Decker RH. Stereotactic radiotherapy in the treatment of primary bronchial carcinoid tumor. *Clin. Lung Cancer.* 16(2), e11–e14 (2015).
- Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Wegner RE. Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis. *Lung Cancer* 124, 283–290 (2018).
- Hasan S, Renz P, Wegner RE et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: A National Cancer Database (NCDB) Analysis. Ann.
   Surg. doi:10.1097/SLA.0000000000003051 (2018) (Epub ahead of print).
- Wegner RE, Abel S, Hassan S et al. The role of adjuvant therapy for atypical bronchopulmonary carcinoids. Lung Cancer 131, 90–94 (2019).
- 17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J. Clin. Epidemiol.* 45(6), 613–619 (1992).
- 18. Meier ELKaP. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53(282), 457-481 (1958).
- 19. D'agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat. Med. 17(19), 2265–2281 (1998).
- Okoye CC, Jablons DM, Jahan TM, Kukreja J, Cardozo S, Yom SS. Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity. Am. J. Clin. Oncol. 37(4), 350–355 (2014).
- Overview of differential approaches in the management of typical versus atypical carcinoid.
- 21. Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J. Thorac. Oncol. 2(7 Suppl 3), S94–S100 (2007).
- 22. Wegner RE, Ahemd N, Hasan S, Schumacher LY, Van Deusen M, Colonias A. SBRT for early stage lung cancer: outcomes from biopsy proven and empirically treated lesions. *Lung Cancer Manag.* 7(1), LMT01 (2018).
- Horne ZD, Richman AH, Dohopolski MJ, Clump DA, Burton SA, Heron DE. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers. Lung Cancer 115, 1–4 (2018).
- 24. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. *Radiother. Oncol.* 101(2), 250–254 (2011).
- 25. Ahmed N, Hasan S, Schumacher L, Colonias A, Wegner RE. Stereotactic body radiotherapy for central lung tumors: finding the balance between safety and efficacy in the 'no fly' zone. *Thorac. Cancer* 9(10), 1211–1214 (2018).